TURANDOT_3 | R Documentation |
Kaplan-Meier digitized data from TURANDOT, figure 3 (PMID 27501767). A reported sample size of 564 for a primary endpoint of OS in breast cancer.
TURANDOT_3
A data frame of 564 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bev_capecitabine, bev_paclitaxel) | |
Zielinski C, Láng I, Inbar M, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17: 1230–9.
summary(TURANDOT_3)
kmplot(TURANDOT_3)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.